Sanofi and the Institut Pasteur Create Four Prestigious Awards
to Support Innovative Biomedical Research

Paris, France - February 27, 2012 - Sanofi (EURONEXT: SAN and NYSE: SNY) and the
Institut Pasteur announced today the creation of the Sanofi-Institut Pasteur Awards to
encourage scientific excellence in the service of health.

Four hundred and eighty thousand euro (480,000 €) will support four innovative research
projects demonstrating real progress in the life sciences and providing answers to major
healthcare problems, more specifically in four fields: neglected tropical diseases, vaccine
innovation, drug resistance, and therapeutic approaches to ageing and regenerative
medicine.

The jury is composed of seven prestigious members: Prof. Peter C. Agre, John Hopkins
University, Baltimore, United States, Nobel Prize in Chemistry 2003, Prof. Elizabeth H.
Blackburn, University of California, San Francisco, Nobel Prize in Medicine 2009, Prof.
Pascale Cossart, Head of the Bacteria-Cell Interactions Unit, Institut Pasteur, Prof. Alice
Dautry, President of the Institut Pasteur, Prof. Depei Liu, Vice President of the Academy of
Engineering of China and President of the Chinese Academy of Medical Sciences and the
Peking Union Medical College, Dr Robert Sebbag, Vice President, Access to Medicines,
Sanofi, and Dr Elias Zerhouni, President, Global R&D, Sanofi.

“With these awards, the Institut Pasteur confirms its commitment to the greater interest by
encouraging research, notably in conditions affecting the most vulnerable populations and
diseases sharply on the rise in the world,” said Alice Dautry, President of the Institut Pasteur.
“I am enthusiastic about this collaborative endeavour with the Institut Pasteur which will
promote and support research teams capable of making a real difference in the lives of
patients and in key areas of public health,” said Elias Zerhouni, President, Global R&D of
Sanofi. “The Sanofi-Institut Pasteur Awards follow a long-standing partnership between our
two organizations.”

Candidates can submit their applications by April 20, 2012. The prices will be awarded in
November 2012 at the Institute Pasteur in Paris. For further information: www.sanofiinstitutpasteur-awards.com

Sanofi and the Institut Pasteur have a long history of partnership which reflects Louis
Pasteur philosophy which states that "Pure research and applied research are not separate
entities. Research and its applications are united together as the fruit of the tree is united
with the branch that bears it”.

The first partnership emerged through the establishment of the dedicated fund "Fighting
Parasitic Diseases" which led to the creation of new research teams. Today, Sanofi also
sponsors the Center for Integrative Biology of Emerging Diseases (BIME) and collaborates
with the Institut Pasteur in the development of new vaccines against infectious diseases.


About the Institut Pasteur
An internationally renowned center of biomedical research, the Institut Pasteur, created in
1887 by Louis Pasteur, is a recognized private non-profit foundation. Its mission is to
contribute to preventing and fighting disease in France and around the world, through
scientific and medical research, education, and public health activities. About 2600
individuals work on its campus in Paris. In addition to research in the field of life sciences, a
significant part of its work is dedicated to the study of infectious, genetic and neurodegenerative diseases as well as certain cancers. The Institut Pasteur is at the heart of an
international network comprising 32 institutes on 5 continents. Since its creation, 10
researchers have received the Nobel Prize in Medicine. www.pasteur.fr


About Sanofi
Sanofi, a global and diversified healthcare leader, discovers, develops and distributes
therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of
healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative
drugs, rare diseases, consumer healthcare, emerging markets and animal health. Sanofi is
listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).